Hormone therapies ”up breast cancer metastasis risk in post-menopausal women”

Washington, May 7 (ANI): A University of Missouri study has found that hormone therapies not just increase the risk of breast cancer in post-menopausal women, they can also increase the chance of the cancer metastasising.

After menopause, women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries.

Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus.

Previous studies have shown that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.

Now, the new study has demonstrated that progestins can also increase the chance of the cancer metastasizing, or spreading to the lymph nodes.

“In our study, we found that progestins increase the number of blood vessels that are responsible for transporting existing cancer cells,” said Salman Hyder, the Zalk Endowed Professor in Tumour Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center.

“The more the blood vessels increase, the higher the chance of cancer cell metastasizing. Progestins could even be more harmful to women who have functionally abnormal p53, a protein that acts as a tumour suppressor. In the absence of p53, progestins increase the release of a protein from tumour cells that allows formation of new blood vessels within tumours.”

In the study, researchers compared the effects of several types of commonly used progestins on breast cancer tumours in an animal model. Researchers found that all types of progestin tested act in the same way and increased the risk of metastasis.

Also, results showed that estrogen and progestin acted the same way whether taken together or separately. Although Hyder said that the study was independent of whether or not the ovaries were intact, it”s still unclear whether progestins have the same effects in pre-menopausal women.

“Especially if there”s a family history of breast cancer, it”s advisable not to take progestins. It”s a difficult call that must be made on an individual basis by a physician,” Hyder said.

“The next step for this research is finding a type of progestin that does not cause tumor progression but still protects the uterus. Also, we”re trying to see if it”s possible to give patients something in addition to estrogen and progestin that can protect the breast,” Hyder added.

The study has been accepted for publication in the Journal Menopause. (ANI)

How sex hormones control ‘masculinization’ of the brain

Washington, Apr 29 (ANI): A new study has uncovered some information about how sex hormones control masculinization of the brain during development and drive gender related behaviors in adult males.

Published by Cell Press in the April 29 issue of the journal Neuron, the study demonstrates that direct action of testosterone, the prototypical male hormone, is unnecessary for masculinizing the brain and behavior.

Testosterone and estrogen are thought to play an essential role in organizing and activating gender-specific patterns of behavior in sexually reproducing animals.

Testosterone is produced by the testes and directly activates the androgen receptor (AR) in target tissues such as muscle. Estrogen is produced by the ovaries and is nearly undetectable in the circulation of males of most species. However, circulating testosterone in males can be converted into estrogen in the brain, and this testosterone-derived estrogen has been shown to control many male behaviors.

“It was known that testosterone and estrogen are essential for typical male behaviors in many vertebrate species,” explains the study”s senior author, Dr. Nirao M. Shah from the Department of Anatomy at the University of California, San Francisco. “However, how these two hormones interact to control masculinization of the brain and behavior remained to be established.”

Dr. Shah and colleagues found that during the neonatal testosterone surge there is very little AR expressed in the developing brain, making it unlikely that testosterone signaling via AR plays a major role in masculinizing neural pathways. Importantly, they went on to show that the male pattern of AR expression in the brain was dependent on testosterone-derived estrogen signaling.

The researchers then used a genetic approach to knock out the AR in the mouse nervous system and observed that these mutants still exhibited male type mating, fighting, and territorial marking behaviors. However, these mutant males had striking reductions in specific components of these masculine behaviors. These results show that testosterone signaling via AR does not control masculine differentiation of the brain and behavior but regulates the frequency and extent of male typical behaviors.

“Our findings in conjunction with previous work suggest a model for the control of male pattern behaviors in which estrogen masculinizes the neural circuits for mating, fighting, and territory marking, and testosterone and estrogen signaling generate the male typical levels of these behaviors,” concludes Dr. Shah. “It will be interesting in future studies to identify the molecular and circuit level mechanisms that are controlled by these hormones.” (ANI)

Long-term tamoxifen use may up aggressive breast cancer risk

Washington, Aug 26 (ANI): Tamoxifen drug, commonly used for treating breast cancer, can actually increase the severity of the disease, finds a new study.

The researchers showed that long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer.

Lead researcher Dr Christopher Li at Fred Hutchinson Cancer Research Centre compared the breast-cancer patients who received the estrogen-blocking drug tamoxifen to those who did not and found that while the drug was associated with a 60 percent reduction in estrogen receptor-positive, or ER positive, second breast cancer – the more common type, which is responsive to estrogen-blocking therapy – it also appeared to increase the risk of ER negative second cancer by 440 percent.

“This is of concern, given the poorer prognosis of ER-negative tumors, which are also more difficult to treat,” said Li.

The findings from the new study supports Li’s earlier research suggesting a link between long-term tamoxifen use and an increased risk of ER-negative second cancers.

“The earlier study had a number of limitations. For example, we did not have information on the duration of tamoxifen therapy the women received,” said Li.

“The current study is larger, is based on much more detailed data, and is the first study specifically designed to determine whether tamoxifen use among breast cancer survivors influences their risk of different types of second breast cancers,” the expert added.

However, Li insists that while the study confirmed a strong association between long-term tamoxifen therapy and an increased risk of ER-negative second cancer, it does not suggest that breast cancer survivors should stop taking hormone therapy to prevent a second cancer.

The findings are published in the journal Cancer Research. (ANI)

Menopause transition may cause temporary memory loss,learning trouble

Washington, May 26 (ANI): Women going through the menopause suffer from temporary loss of memory and learning ability, according to a new study.

The largest study of its kind to date has been published in the May 26, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

For a four-year period, researchers studied 2,362 women, who were between the ages of 42 and 52 had at least one menstrual period in the three months before the study started.

The women were given three tests: verbal memory, working memory and a test that measured the speed at which they processed information.

Scientists tested the women throughout four stages of the menopause transition: premenopausal (no change in menstrual periods), early perimenopausal (menstrual irregularity but no “gaps” of 3 months), late perimenopausal (having no period for three to 11 months) and postmenopausal (no period for 12 months).

The study found that processing speed improved with repeated testing during premenopause, early perimenopause and postmenopause, but that scores during late perimenopause did not show the same degree of improvement.

Improvements in processing speed during late perimenopause were only 28 percent as large as improvements observed in premenopause. For verbal memory performance, compared to premenopause, improvement was not as strong during early and late perimenopause. Improvements in verbal memory during early perimenopause were 29 percent as large as improvements observed in premenopause. During late perimenopause, verbal memory improvement was seven percent as large as in premenopause.

Combined, these findings suggest that during the early and late perimenopause women do not learn as well as they do during other menopause transition stages.

“These perimenopausal test results concur with prior self-reported memory difficulties–60 percent of women state that they have memory problems during the menopause transition,” said Gail Greendale, MD, with the David Geffen School of Medicine at the University of California, Los Angeles.

“The good news is that the effect of perimenopause on learning seems to be temporary. Our study found that the amount of learning improved back to premenopausal levels during the postmenopausal stage,” the expert added.

The study also found that taking estrogen or progesterone hormones before menopause helped verbal memory and processing speed. In contrast, taking these hormones after the final menstrual period had a negative effect: postmenopausal women using hormones showed no improvement in either processing speed scores or verbal memory scores, unlike postmenopausal women not taking hormones.

“Our results suggest that the ‘critical period’ for estrogen or progesterone’s benefits on the brain may be prior to menopause, but the findings should be interpreted with caution,” said Greendale. (ANI)

Nerve pain pill found effective in treating hot flashes

Washington, May 16 (ANI): A pill used to treat nerve pain has been found effective in treating hot flashes in women, claim Mayo Clinic researchers.

They have found that pregabalin decreased hot flash severity and frequency about 20 percent more than did a placebo.

Pregabalin has been found to offer about the same benefit as gabapentin, an older, related drug, as well as newer classes of antidepressants.

“Hot flashes are a major problem in many women, and for those who opt not to take hormonal therapies or antidepressants, pregabalin appears to be another treatment option,” said the study’s lead author, Charles Loprinzi, M.D., a medical oncologist at the Mayo Clinic in Minnesota.

Women who use pregabalin only need to take two pills a day, versus three for gabapentin, he added.

Gabapentin and a variety of antidepressants are commonly prescribed for treatment of hot flashes and pregabalin is a newer version of gabapentin.

Dr. Loprinzi and colleagues set up a 207-participant study conducted by the North Central Cancer Treatment Group (NCCTG). Patients getting pregabalin started off with lower doses which were increased weekly to the eventual full dose.

The researchers found that for the 163 patients both doses of pregabalin reduced hot flashes to about the same degree, but that toxicities, such as cognitive dysfunction, were increased at the higher dose.

After six weeks of treatment, women receiving pregabalin showed 65 percent decrease in hot flashes compared to 50 percent decrease in those receiving placebo.

“All in all, this study demonstrates that we have another agent to add to the list of medications that offer benefit against hot flashes, even in women using anti-estrogen therapies,” said Dr. Loprinzi .

The findings were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). (ANI)

Sex hormone oestrogen controls sound processing in the brain

Washington, May 6 (ANI): University of Rochester scientists in New York have found that sex hormone oestrogen controls how the brain processes sounds.

This is the first time that any study has shown that a sex hormone can directly affect auditory function.

The researchers say that their study points toward the possibility that oestrogen controls other types of sensory processing as well.

According to them, understanding how oestrogen changes the brain’s response to sound may open the door to new ways of treating hearing deficiencies.

“We’ve discovered estrogen doing something totally unexpected. We show that estrogen plays a central role in how the brain extracts and interprets auditory information. It does this on a scale of milliseconds in neurons, as opposed to days, months or even years in which estrogen is more commonly known to affect an organism,” says Raphael Pinaud, assistant professor of brain and cognitive sciences at the University of Rochester and lead author of the study.

The researcher has revealed that past studies have already hinted at a connection between oestrogen and hearing in women who have its low levels, something that often occurs after menopause.

He, however, insists that no one actually knew that oestrogen plays such a direct role in determining auditory functions in the brain.

“Now it is clear that estrogen is a key molecule carrying brain signals, and that the right balance of hormone levels in men and women is important for reasons beyond its role as a sex hormone,” says Pinaud.

Working in collaboration with Assistant Professor Liisa Tremere and postdoctoral fellow Jin Jeong, Pinaud showed that increasing oestrogen levels in brain regions, which process auditory information, caused heightened sensitivity of sound-processing neurons, which encoded more complex and subtle features of the sound stimulus.

He reveals that when the actions of oestrogen were blocked, or brain cells were prevented from producing the hormone within auditory centres, the signalling that is necessary for the brain to process sounds shut down.

His team have also shown that oestrogen is required to activate genes that instruct the brain to lay down memories of those sounds.

“It turns out that estrogen plays a dual role. It modulates the gain of auditory neurons instantaneously, and it initiates cellular processes that activate genes that are involved in learning and memory formation,” says Pinaud.

Pinaud and his colleagues made these findings while studying how oestrogen may help change neuronal circuits to form memories of familiar songs in a type of bird typically used to understand the biology of vocal communication.

“Based on our findings we must now see estrogen as a central regulator of hearing. It both determines how carefully a sound must be processed, and activates intracellular processes that occur deep within the cell to form memories of sound experiences,” he says.

The researchers will continue their work studies to find out how neurons adapt their functionality when encountering new sensory information, and how these changes may ultimately enable the formation of memories.

They also will continue exploring the specific mechanisms by which estrogen might impact these processes.

“While we are currently conducting further experiments to confirm it, we believe that our findings extrapolate to other sensory systems and vertebrate species,” says Pinaud. “If this is the case, we are on the way to showing that estrogen is a key molecule for processing information from all the senses.”

The study has been published in The Journal of Neuroscience. (ANI)

Genetic test may help determine heart surgery complication risk

Washington, May 1 (ANI): A new study has revealed that a simple genetic test can help determine a patient’s risk of developing complications following cardiac surgery.

While cardiac surgery puts an individual at risk for developing shock and kidney failure, there are no effective medications to prevent these complications.

When shock occurs, patients are often given norepinephrine to stimulate their blood vessels and normalize their blood pressure however, people respond differently to the medication.

Lead researchers Duska Dragun and Anja Haase-Fielitz, from Charite Universitatsmedizin Berlin, Germany, studied the gene that encodes COMT in 260 patients who underwent heart bypass surgery.

They found that a particular genetic variant in some individuals can lead to lower activity of the COMT enzyme, which makes them less responsive to norepinephrine’s effects.

People who had this variant (called LL) were more likely to develop shock and kidney failure, requiring a hospital stay for a longer period of time.

The link between the COMT LL variant and these complications may be pronounced in women because protective estrogen metabolites can be inactivated by norepinephrine.

The researchers claim that if the results are confirmed in larger clinical trials, physicians could use a COMT gene test to help them determine a patient’s risk of developing complications following cardiac surgery and could therefore help them prepare for their patient’s post-surgery care. (ANI)

PET plastic bottles maybe harmful for health

Melbourne, April 29 (ANI): Drinking out of water bottles made from PET plastic may pose a human health risk, reveals a new study.

According to lead researcher Martin Wagner, Goethe University, Frankfurt, a questionable finger could be raised on the safety of the PET plastic water bottles.

The study found that estrogenic compounds trickle into the water in bottles made from PET (polyethylene terephthalate).

And some yet-to-be-identified chemicals in these plastics seemed to have the potential to meddle with estrogen and other reproductive hormones.

“What we found was really surprising to us. If you drink water from plastic bottles, you have a high probability of drinking estrogenic compounds,” ABC Science quoted Wagner as saying.

But Wagner and his team warned that it was still too early to conclude if PET plastics were a cause of concern in relations to human health.

Shanna Swan, an epidemiologist at the University of Rochester School of Medicine and Dentistry in New York, added maybe a revised review of so-called “safe” plastics was required.

Swan said: “This is coming at a good time because the use of bottles for consuming water is getting very bad press now because of its carbon footprint.

She continued: “This raises questions about all plastic bottles.” (ANI)

Hormone therapy may protect women from colorectal cancer

Washington, April 23 (ANI): A team of researchers led by Mayo Clinic scientists has found that hormone therapy use is linked to a significantly lower colorectal cancer risk.

However, the mechanisms for the apparent protective association are still unclear.

The study was designed to look at possible links between estrogen exposure and colon cancer molecular subtypes, to determine how these hormones might function as anti-cancer agents.

“In our large, prospective study, use of hormone therapy seemed to be beneficial with respect to reducing colorectal cancer risk – women who did use these drugs had a 28 percent lower incidence rate than women who did not use these drugs,” says the study’s lead author, David Limsui, M.D., a fellow in the Department of Gastroenterology at Mayo Clinic’s campus in Rochester, Minn.

“But we still don’t know how estrogen compounds work in cancer prevention, which is intriguing,” he added.

Women who reported using other hormone preparations, such as oral contraceptives, did not appear to derive any colorectal cancer prevention benefits.

“Based on our findings, we need to continue exploring the cancer pathways that might be affected by these hormones,” Limsui said.

In the study, the researchers examined tumour tissue from 553 colorectal cancer patients, specifically looking for associations between self-reported hormone use and a specific DNA methylation pattern, called the CpG island methylator phenotype, or BRAF gene mutations.

No associations were detected between hormone use and these molecular markers.

The study is being presented at the AACR 100th Annual Meeting 2009. (ANI)

Oral contraceptives ‘increase lupus risk’

Washington, April 8 (ANI): Use of oral contraceptives is associated with an increased risk of autoimmune disease systemic lupus erythematosus, a new study has shown.

The study found that the risk was mostly limited to current users, those who had just started using contraception, and those using older first- and second-generation oral contraceptives instead of third-generation ones.

Led by Dr. Samy Suissa of the Centre for Clinical Epidemiology at Jewish General Hospital of McGill University in Montreal, researchers obtained data on more than 1.7 million women ages 18-45 from the U.K. General Practice Research Database, which contains more than 6 million people.

The women all had prescriptions for combined oral contraceptives (COCs) containing estrogen and progestogen.

During an average of eight years of follow-up, 786 women had a first-time diagnosis of SLE. Each case was matched with up to 10 controls among women without SLE at the time of the case’s diagnosis.

The results showed that the use of COCs was associated with a significant increased risk of newly diagnosed SLE.

This was mostly limited to the first three months of use with first- and second-generation contraceptives containing higher doses of estrogen, suggesting “an acute effect in susceptible women and possibly a dose-response effect of estrogen on SLE onset,” according to the researchers.

They note that estrogen can directly modulate the immune response, which could complete the action of some sex-linked genes and contribute to the genetic predisposition of the disease, and it has also been shown to have an effect on the breakdown of immune tolerance seen in SLE.

“Our findings that longer-term use of contraceptives is associated with an increased risk of incident SLE (albeit of lower magnitude) and that current use of contraceptives with higher doses of ethinyl estradiol is associated with an increased risk of incident SLE, suggest a possible dose-response effect of estrogen on SLE onset, which could be an alternative or additional mechanism to favor occurrence of the disease,” the authors said.

They note that the absence of significant increased risk in third-generation contraceptives may be related to the lower doses of estrogen compared to earlier generations.

The study was published in the April issue of Arthritis Care and Research. (ANI)

Is your bottled mineral water ‘clean’?

Washington, March 27 (ANI): Those who think mineral water is “clean” better think again, for a study in Germany has suggested that plastic mineral water bottles contaminate drinking water with estrogenic chemicals.

Martin Wagner and Jorg Oehlmann, from the Department of Aquatic Ecotoxicology at the Goethe University in Frankfurt am Main, analysed commercially available mineral waters, and found evidence of estrogenic compounds leaching out of the plastic packaging into the water.

The researchers say that these chemicals are potent in vivo and result in an increased development of embryos in the New Zealand mud snail.

This is the first time that any research team have shown that substances leaching out of plastic food packaging materials act as functional estrogens.

Wagner and Oehlmann looked at whether the migration of substances from packaging material into foodstuffs could contribute to human exposure to man-made hormones.

The researchers analysed 20 brands of mineral water available in Germany – nine bottled in glass, nine bottled in plastic, and two bottled in composite packaging (paperboard boxes coated with an inner plastic film).

Water samples were taken from the bottles, and tested for the presence of estrogenic chemicals in vitro.

The study group later conducted a reproduction test with the New Zealand mud snail to determine the source and potency of the xenoestrogens.

Wagner and Oehlmann say that they found estrogen contamination in 60 per cent of the samples they had analysed.

According to the researchers, mineral waters in glass bottles were less estrogenic than waters in plastic bottles.

They said that 33 per cent of all mineral waters bottled in glass compared with 78 per cent of waters in plastic bottles, and both waters bottled in composite packaging, showed significant hormonal activity.

When the researcher bred the New Zealand mud snail in both plastic and glass water bottles, they observed more than double the number of embryos in plastic bottles compared with glass bottles.

Together, said the team, the findings showed widespread contamination of mineral water with potent man-made estrogens that partly originate from compounds leaching out of the plastic packaging material.

The authors concluded: “We must have identified just the tip of the iceberg in that plastic packaging may be a major source of xenohormone contamination of many other edibles. Our findings provide an insight into the potential exposure to endocrine-disrupting chemicals due to unexpected sources of contamination.”

The study has been published in Springer’s journal Environmental Science and Pollution Research. (ANI)

Black women three times more likely to develop aggressive breast cancer

Washington, Mar 25 (ANI): Black women are three times more likely than whites to develop aggressive breast cancer, according to a new study.

The research team led by Dr Carol Rosenberg at Boston University School of Medicine has found that despite lifestyle, age and weight black women face three fold risk of developing an aggressive ‘triple negative tumour’.

During the study, the researchers focused on 415 breast cancer cases.

They looked at clinical features particularly patient age, weight and race/ethnicity, and pathological features including the triple-negative pattern – tumours that lack expression of the estrogen receptor, the progesterone receptor and the HER2 gene.

“The odds of having a triple negative tumour were three times higher for black women than for non-black women in the study,” said Rosenberg.

“Previously, it was known that pre-menopausal black women had more triple negative tumours. What we found that was new was that these tumours were just as common in black women diagnosed before or after age 50, and in those who were or were not obese.

“The higher prevalence of triple negative breast tumours in black women in all age and weight categories likely contributes to black women’s unfavourable breast cancer prognosis,” she added. (ANI)

Osteoporosis may raise vertigo risk

Washington, Mar 24 (ANI): Osteoporosis patients are more likely to also have vertigo, says a new study.

The study, published in the March 24, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology, involved 209 people with benign positional vertigo with no known cause such as head trauma or ear surgery.

Vertigo is an inner ear disorder that is a common cause of dizziness. The disorder is believed to be caused by loose calcium carbonate crystals that move in the sensing tubes of the inner ear.

The people with vertigo were compared to 202 people with no history of dizziness. People with osteoporosis, or low bone density, were three times more likely to have vertigo, and people with osteopenia, which is the stage before osteoporosis, were twice as likely to have vertigo as people who had normal bone density.

In women, 25 percent of those with vertigo had osteoporosis, compared to nine percent of those who did not have vertigo, and 47 percent of those with vertigo had osteopenia, compared to 33 percent of those without vertigo.

For men, 12 percent of those with vertigo had osteoporosis, compared to six percent of those without vertigo, and 40 percent of those with vertigo had osteopenia, compared to 27 percent of those without vertigo.

“These findings suggest a problem with calcium metabolism in people with vertigo,” said study author Ji Soo Kim, MD, PhD, of Seoul National University College of Medicine in Korea.

“Women most often have their first case of vertigo in their 50s, when they are also having a drop in bone mass due to loss of estrogen. Estrogen is one of the main hormones that influence calcium and bone metabolism,” th expert added. (ANI)

Why men like wet kisses with more ‘tongue action’

Washington, Feb 18 (ANI): When you share a kiss with your man, you reveal a lot more than just passion. US scientists have found that modern man uses smooch to pick up traces of estrogen in a woman’s saliva and thus gauge her fertility.

Anthropologist Helen Fisher of Rutgers University says that such behaviour may explain why men like wet kisses with more “tongue action”.

While at a meeting of the American Association for the Advancement of Science in Chicago, Fisher said that wet kisses could also be an unconscious attempt to transfer testosterone to the woman, which would stimulate her sexual interest.

“Men see kissing early in a relationship directly as a step to copulation,” she said.

According to Wendy Hill, a neuroscientist at Lafayette College in Easton, Pennsylvania, kissing may also serve as a way to assess the quality of a mate.

Fisher said that research has shown that the majority of men and women rate their first kiss as either “the kiss of death” or the blossoming of a new relationship.

The expert recently developed a personality test that measures four universal temperaments by using statistics from 40,000 people on the Internet dating site Chemistry.com.

Each temperament type was linked to activity levels of the brain chemicals dopamine/norepinephrine, serotonin, testosterone, and estrogen/oxytocin.

Fisher found that a person’s temperament guides which type of mate they select-boosting her belief that love involves some very powerful brain chemistry.

“People sing for love; they dance for love; they write about love; live for, kill, and die for love,” Fisher told National Geographic News.

“It’s a wonderful addiction when [a relationship is] working well-but perfectly horrible when it’s working poorly,” she added. (ANI)

High sex hormone levels ‘make women unfaithful’

London, Jan 14 (ANI): Ladies who have extra-marital affairs can blame it on their hormones, claims a new study, which found that women with high levels of estrogen not only look and feel pretty – but are also more prone to hop from man to man.

strogen, the so-called female hormone, affects fertility and makes women dress more provocatively.

Dr. Kristina Durante of The University of Texas at Austin and colleagues found that young women felt more attractive when they had high levels of an estrogen known as estradiol, and they acted on those feelings, reports New Scientist.

“These women are willing to trade up when the opportunity arises and continue to extract these lucrative resources from men when they can,” says Kristina Durante, an evolutionary psychologist at the University of Texas in Austin, who led the study.

She thinks the behaviour could be an adaptation to the high costs of giving birth.

“For women it’s all about the resources that we need. If you’re going to be getting knocked up there’s a significant cost,” she says.

To reach the conclusion, Durante’s team tested 52 female undergraduates aged 17 to 30 who were not taking hormone contraceptives. They took two estradiol samples from each, as hormone levels fluctuate from week to week.

They had the women rate their own attractiveness and showed their photographs to others to rate, as well.

As independent confirmation, a panel of two men and seven women also judged them the prettiest.

High oestradiol women reported that they had dated more men and were more willing to cheat, from innocent flirts to serious affairs. These women, however, proved no more interested in one-night stands than women with lower levels of oestradiol.

The study has been published in the journal Biology Letters. (ANI)

Three simple steps to treat erectile dysfunction

Washington, Feb 5 (ANI): Is erectile dysfunction taking the joy out of your sex life? Take heart, for Temple urologist Jack Mydlo has offered three simple steps to get back the pleasure – cut back on fat, control cholesterol, and kick the butt.

Men often rely on the “little blue pill” to score in the bedroom but following these three simple steps can improve their performance without a visit to the doctor or a drugstore.

After diabetes and high blood pressure the next culprit in the line for erectile dysfunction (ED) is cigarette.

“The number one thing we can do to stop erectile dysfunction is to stop smoking. It’s the number one environmental cause of ED in our society,” said Mydlo.

It restricts the blood flow to the penis. He said it takes 12 to 24 months for better function once you quit the habit.

Men with high cholesterol are at two fold risk of developing ED.

“Men with a cholesterol level of 240 or higher have almost a twofold increase of ED compared to a man who has lower cholesterol numbers,” said Mydlo.

High levels of cholesterol lead to plaque buildup in tubes (in the penis and arteries, which can greatly reduce blood flow.

Obesity is to blame not only for men with self-esteem issues involving their appearance, but also their performance.

“Adipose tissue in body fat converts testosterone to estrogen, and lower levels of testosterone can make it difficult for a man to achieve an erection, no matter how many pills they take,” said Mydlo.

Losing weight will improve the testosterone to estrogen ratio, which may improve sex drive, or libido, as well as erections. It also decreases cholesterol, which will help improve blood flow. (ANI)

Statins ineffective in breast cancer prevention: Study

Washington, Feb 5 (ANI): Statins, commonly used for lowering cholesterol levels, are ineffective in preventing breast cancer, according to researchers.

Prior studies have shown some but limited efficacy in breast cancer models when these drugs were given through a method that would be the equivalent of intravenously in humans.

However, that is not the way people take statins.

During the study, scientists conducted laboratory work in animals to determine if drugs like atorvastatin and lovastatin actually prevent both ER-positive and ER-negative breast cancer.

“We saw no real efficacy from either statin,” said Ronald Lubet, Ph.D., an NCI program director.

Atorvastatin was administered at either 125 or 500 mg/kg in the diet of rats, and it did not alter the incidence of estrogen receptor-positive mammary cancers or its multiplicity. Similarly, no effect of atorvastatin was observed in an estrogen receptor-negative model in mice.

Lovastatin was given at 100 and 500 mg/kg, and it showed no significant preventive -effect similar to atorvastatin.

Lubet said the research into statin use and cancer prevention would continue.

“There is always the question of whether there will be a subset of breast cancer where this class of agents will be effective, but the answer at this point is that the present preclinical studies do not support the use of statins as general breast cancer preventive agents” he added.

The study appears in Cancer Prevention Research, a journal of the American Association for Cancer Research. (ANI)

Risk factors for contralateral breast cancer identified

Washington, Jan 27 (ANI): Researchers from The University of Texas M. D. Anderson Cancer Centre have identified certain risk factors that may help predict the likelihood of patients developing breast cancer in the opposite breast.

These risk factors may help women who are diagnosed with breast cancer make the difficult decision about whether to have their second breast removed as a preventive step.

“Women often consider contralateral prophylactic mastectomy (CPM) not because of medical recommendation, but because they fear having their breast cancer return,” said Kelly Hunt, M.D., professor in the Department of Surgical Oncology at M. D. Anderson and lead author on the study.

“Currently it is very difficult to identify which patients are at enough risk to benefit from this aggressive and irreversible procedure. Our goal was to determine what characteristics defined these high-risk patients to better inform future decisions regarding CPM,” she added.

During the study, the researchers reviewed the cases of 542 women with breast cancer only in one breast who received CPM to remove the second breast.

Out of this group, 435 patients had no abnormal pathology identified in the opposite breast, 25 patients had contralateral breast cancer identified at surgery, and 82 patients had abnormal cells that indicate a moderate to high-risk for breast cancer development in the contralateral breast found at the time of surgery.

Further analysis of the patients with contralateral breast cancer revealed that a five-year Gail risk of 1.67 percent or greater; an invasive lobular histology; and multiple tumours in the original breast were all strong predictors for contralateral breast cancer.

However, patient race, estrogen receptor status and progesterone receptor status were not associated with increased risk.

“We went from having very little information on the benefit of this procedure for individual patients to identifying three independent and significant risk factors,” Hunt said.

“Each provides valuable insight into how likely a woman is to develop the disease in her other breast and enables physicians to make an educated recommendation if a patient will potentially benefit from CPM.

“We’ve always known contralateral breast cancer risk is not the same for all women and it is unnecessary to perform preventive mastectomies routinely.

“As we begin to clarify the specific risk factors, the number of women undergoing CPM may decrease and those with a low to moderate-risk may be more open to less extreme options for risk reduction, such as hormonal therapy and newer agents for prevention of breast cancer,” she added.

The findings are published in journal Cancer. (ANI)

Hormone replacement therapy cuts colorectal cancer risk in women

Washington, Jan 8 (ANI): A new study has shown that hormone replacement therapy can significantly reduce the risk of colorectal cancer in postmenopausal women.

The researchers found that women who had completed use of estrogen plus progestin five or more years previously were 45 pct less likely to develop colorectal cancer

“Compared to women who had never taken these hormones, the use of estrogen plus progestin was associated with a reduced risk of colorectal cancer,” said Jill R. Johnson, M.P.H., a doctoral student at the University of Minnesota School of Public Health.

During the study, the research team led by Johnson extracted data from 56,733 postmenopausal women who participated in the Breast Cancer Detection Demonstration Project follow-up study.

They identified 960 new cases of colorectal cancer in this population.

The findings revealed that any use of estrogen therapy was associated with a 17 percent reduced risk in colorectal cancer.

Among those who used estrogen, the largest reductions were seen among those who were current users (25 percent reduced risk) and users of ten or more years duration (26 percent reduced risk).

However, a 22 percent reduced risk was observed among those who had ever used estrogen plus progestin in combination.

They further found a 36 percent reduction in risk among those who had used progestin sequentially or less than 15 days per month.

Past users of estrogen plus progestin, who had stopped at least five years ago, had a 45 percent risk reduction.

The study is published in the January issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research. (ANI)